

## 7. Literaturverzeichnis

1. Clemens A, Riemann JF and Siegel EG: Optimized diabetes therapy in type 2 diabetics. *Med Klin (Munich)*. 98(9), 484-92. (2003).
2. Saltiel AR: New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. *Cell*. 104(4), 517-29. (2001).
3. Saltiel AR and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. *Nature*. 414(6865), 799-806. (2001).
4. Klip A and Paquet MR: Glucose transport and glucose transporters in muscle and their metabolic regulation. *Diabetes Care*. 13(3), 228-43. (1990).
5. Speakman JR: Obesity: the integrated roles of environment and genetics. *J Nutr*. 134(8 Suppl), 2090S-2105S (2004).
6. Mokdad AH, Bowman BA, Ford ES, et al.: The continuing epidemics of obesity and diabetes in the United States. *Jama*. 286(10), 1195-200 (2001).
7. Seidell JC: Obesity in Europe: scaling an epidemic. *Int J Obes Relat Metab Disord*. 19 Suppl 3S1-4 (1995).
8. James PT, Rigby N and Leach R: The obesity epidemic, metabolic syndrome and future prevention strategies. *Eur J Cardiovasc Prev Rehabil*. 11(1), 3-8 (2004).
9. Deckelbaum RJ and Williams CL: Childhood obesity: the health issue. *Obes Res*. 9 Suppl 4239S-243S (2001).
10. Sorof J and Daniels S: Obesity hypertension in children: a problem of epidemic proportions. *Hypertension*. 40(4), 441-7 (2002).
11. Koubova J and Guarente L: How does calorie restriction work? *Genes Dev*. 17(3), 313-21 (2003).
12. Lee DW and Yu BP: Modulation of free radicals and superoxide dismutases by age and dietary restriction. *Aging (Milano)*. 2(4), 357-62. (1990).
13. Cock TA, Houten SM and Auwerx J: Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. *EMBO Rep*. 5(2), 142-7. (2004).
14. Guarente L: Sir2 links chromatin silencing, metabolism, and aging. *Genes Dev*. 14(9), 1021-6. (2000).
15. Smith BA, Edwards MS, Ballachey BE, Cramer DA and Sutherland TM: Body weight and longevity in genetically obese and non-obese mice fed fat-modified diets. *Growth Dev Aging*. 55(2), 81-9. (1991).
16. Kopelman PG: Obesity as a medical problem. *Nature*. 404(6778), 635-43. (2000).
17. Ni Mhurchu C, Bennett D, Lin R, et al.: Obesity and health-related quality of life: results from a weight loss trial. *N Z Med J*. 117(1207), U1211. (2004).
18. Bjorntorp P: Metabolic implications of body fat distribution. *Diabetes Care*. 14(12), 1132-43. (1991).
19. Moller DE and Kaufman KD: Metabolic Syndrome: A Clinical and Molecular Perspective. *Annu Rev Med*. 1111 (2004).
20. Randle PJ, Garland PB, Hales CN and Newsholme EA: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *Lancet*. 1785-9. (1963).
21. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. *Diabetes*. 44(8), 863-70. (1995).
22. Goldstein BJ: Insulin resistance as the core defect in type 2 diabetes mellitus. *Am J Cardiol*. 90(5A), 3G-10G. (2002).

23. Berg AH, Combs TP, Du X, Brownlee M and Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. *Nat Med.* 7(8), 947-53. (2001).
24. Rangwala SM, Rich AS, Rhoades B, et al.: Abnormal glucose homeostasis due to chronic hyperresistinemia. *Diabetes.* 53(8), 1937-41. Epub 2004 Jun 09. (2004).
25. Carey DG, Jenkins AB, Campbell LV, Freund J and Chisholm DJ: Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. *Diabetes.* 45(5), 633-8. (1996).
26. Barzilai N, She L, Liu BQ, et al.: Surgical removal of visceral fat reverses hepatic insulin resistance. *Diabetes.* 48(1), 94-8. (1999).
27. Kahn BB: Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. *Cell.* 92(5), 593-6. (1998).
28. Kerner W, Brückel J and Böhm BO: Definition, Klassifizierung und Diagnostik der Diabetes Mellitus. Deutsche Diabetes Gesellschaft [http://www.deutsche-diabetes-gesellschaft.de/redaktion/Mitteilungen/Leitlinien\(2004\)](http://www.deutsche-diabetes-gesellschaft.de/redaktion/Mitteilungen/Leitlinien(2004))
29. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *Bmj.* 321(7258), 405-12. (2000).
30. Ginsberg HN: Insulin resistance and cardiovascular disease. *J Clin Invest.* 106(4), 453-8. (2000).
31. Rocchini AP, Katch V, Kveselis D, et al.: Insulin and renal sodium retention in obese adolescents. *Hypertension.* 14(4), 367-74. (1989).
32. Hall JE: Louis K. Dahl Memorial Lecture. Renal and cardiovascular mechanisms of hypertension in obesity. *Hypertension.* 23(3), 381-94. (1994).
33. Haffner S and Taegtmeier H: Epidemic obesity and the metabolic syndrome. *Circulation.* 108(13), 1541-5. (2003).
34. Reaven GM: Syndrome X: 6 years later. *J Intern Med Suppl.* 73613-22 (1994).
35. Alexander CM, Landsman PB, Teutsch SM and Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes.* 52(5), 1210-4. (2003).
36. Lorenzo C, Okoloise M, Williams K, Stern MP and Haffner SM: The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. *Diabetes Care.* 26(11), 3153-9. (2003).
37. Picard F and Auwerx J: PPAR(gamma) and glucose homeostasis. *Annu Rev Nutr.* 22167-97. Epub 2002 Jan 04. (2002).
38. Trayhurn P and Beattie JH: Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. *Proc Nutr Soc.* 60(3), 329-39. (2001).
39. Zhang Y, Proenca R, Maffei M, et al.: Positional cloning of the mouse obese gene and its human homologue. *Nature.* 372(6505), 425-32. (1994).
40. Engeli S, Negrel R and Sharma AM: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. *Hypertension.* 35(6), 1270-7 (2000).
41. Kershaw EE and Flier JS: Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab.* 89(6), 2548-56. (2004).
42. Garg A: Acquired and inherited lipodystrophies. *N Engl J Med.* 350(12), 1220-34. (2004).
43. Leow MK, Addy CL and Mantzoros CS: Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated

- metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. *J Clin Endocrinol Metab.* 88(5), 1961-76. (2003).
44. Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. *Nature.* 347(6294), 645-50. (1990).
  45. Vamecq J and Latruffe N: Medical significance of peroxisome proliferator-activated receptors. *Lancet.* 354(9173), 141-8. (1999).
  46. Chawla A, Repa JJ, Evans RM and Mangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. *Science.* 294(5548), 1866-70. (2001).
  47. Kliewer SA, Forman BM, Blumberg B, et al.: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. *Proc Natl Acad Sci U S A.* 91(15), 7355-9. (1994).
  48. Lee CH, Olson P and Evans RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. *Endocrinology.* 144(6), 2201-7. (2003).
  49. Rangwala SM and Lazar MA: Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. *Trends Pharmacol Sci.* 25(6), 331-6. (2004).
  50. Werman A, Hollenberg A, Solanes G, et al.: Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. *J Biol Chem.* 272(32), 20230-5. (1997).
  51. Saladin R, Fajas L, Dana S, et al.: Differential regulation of peroxisome proliferator activated receptor gamma1 (PPARgamma1) and PPARgamma2 messenger RNA expression in the early stages of adipogenesis. *Cell Growth Differ.* 10(1), 43-8. (1999).
  52. Gelman L, Fruchart JC and Auwerx J: An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. *Cell Mol Life Sci.* 55(6-7), 932-43. (1999).
  53. Picard F, Kurtev M, Chung N, et al.: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. *Nature.* 429(6993), 771-6. Epub 2004 Jun 2. (2004).
  54. Spiegelman BM and Heinrich R: Biological control through regulated transcriptional coactivators. *Cell.* 119(2), 157-67 (2004).
  55. Fajas L, Auboeuf D, Raspe E, et al.: The organization, promoter analysis, and expression of the human PPARgamma gene. *J Biol Chem.* 272(30), 18779-89. (1997).
  56. Law RE, Goetze S, Xi XP, et al.: Expression and function of PPARgamma in rat and human vascular smooth muscle cells. *Circulation.* 101(11), 1311-8. (2000).
  57. Jones PS, Savory R, Barratt P, et al.: Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. *Eur J Biochem.* 233(1), 219-26. (1995).
  58. Tontonoz P, Hu E, Graves RA, Budavari AI and Spiegelman BM: mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. *Genes Dev.* 8(10), 1224-34. (1994).
  59. Kubota N, Terauchi Y, Miki H, et al.: PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. *Mol Cell.* 4(4), 597-609. (1999).
  60. Miles PD, Barak Y, He W, Evans RM and Olefsky JM: Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. *J Clin Invest.* 105(3), 287-92. (2000).

61. Deeb SS, Fajas L, Nemoto M, et al.: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nat Genet.* 20(3), 284-7. (1998).
62. Altshuler D, Hirschhorn JN, Klannemark M, et al.: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat Genet.* 26(1), 76-80. (2000).
63. Mori Y, Kim-Motoyama H, Katakura T, et al.: Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. *Biochem Biophys Res Commun.* 251(1), 195-8 (1998).
64. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W and Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. *N Engl J Med.* 339(14), 953-9. (1998).
65. Adams M, Reginato MJ, Shao D, Lazar MA and Chatterjee VK: Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. *J Biol Chem.* 272(8), 5128-32. (1997).
66. Clement K, Hercberg S, Passinge B, et al.: The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. *Int J Obes Relat Metab Disord.* 24(3), 391-3. (2000).
67. Knouff C and Auwerx J: PPAR{gamma} calls for Activation in Moderation: Lessons from Genetics and Pharmacology. *Endocr Rev*, (2004).
68. Cowherd RM, Lyle RE and McGehee RE, Jr.: Molecular regulation of adipocyte differentiation. *Semin Cell Dev Biol.* 10(1), 3-10. (1999).
69. Gregoire FM, Smas CM and Sul HS: Understanding adipocyte differentiation. *Physiol Rev.* 78(3), 783-809. (1998).
70. Tontonoz P, Hu E and Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. *Cell.* 79(7), 1147-56. (1994).
71. Tzamei I, Fang H, Ollero M, et al.: Regulated production of a PPAR-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. *J Biol Chem.* 99 (2004).
72. Hamm JK, Park BH and Farmer SR: A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes. *J Biol Chem.* 276(21), 18464-71. Epub 2001 Feb 27. (2001).
73. Tamori Y, Masugi J, Nishino N and Kasuga M: Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. *Diabetes.* 51(7), 2045-55. (2002).
74. Zhang B, Berger J, Hu E, et al.: Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. *Mol Endocrinol.* 10(11), 1457-66. (1996).
75. Loviscach M, Rehman N, Carter L, et al.: Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. *Diabetologia.* 43(3), 304-11. (2000).
76. Norris AW, Chen L, Fisher SJ, et al.: Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. *J Clin Invest.* 112(4), 608-18. (2003).
77. Hevener AL, He W, Barak Y, et al.: Muscle-specific Pparg deletion causes insulin resistance. *Nat Med.* 9(12), 1491-7. Epub 2003 Nov 16. (2003).

78. Verma NK, Singh J and Dey CS: PPAR- $\gamma$  expression modulates insulin sensitivity in C2C12 skeletal muscle cells. *Br J Pharmacol*, (2004).
79. Forman BM, Tontonoz P, Chen J, et al.: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. *Cell*. 83(5), 803-12. (1995).
80. Yu K, Bayona W, Kallen CB, et al.: Differential activation of peroxisome proliferator-activated receptors by eicosanoids. *J Biol Chem*. 270(41), 23975-83. (1995).
81. Nagy L, Tontonoz P, Alvarez JG, Chen H and Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. *Cell*. 93(2), 229-40. (1998).
82. McIntyre TM, Pontsler AV, Silva AR, et al.: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. *Proc Natl Acad Sci U S A*. 100(1), 131-6. Epub 2002 Dec 26. (2003).
83. Lehmann JM, Moore LB, Smith-Oliver TA, et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). *J Biol Chem*. 270(22), 12953-6. (1995).
84. Fukui Y, Masui S, Osada S, Umesono K and Motojima K: A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAY obese mice. *Diabetes*. 49(5), 759-67. (2000).
85. Reginato MJ, Bailey ST, Krakow SL, et al.: A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. *J Biol Chem*. 273(49), 32679-84. (1998).
86. Henke BR, Blanchard SG, Brackeen MF, et al.: N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. *J Med Chem*. 41(25), 5020-36. (1998).
87. Rocchi S, Picard F, Vamecq J, et al.: A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. *Mol Cell*. 8(4), 737-47. (2001).
88. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM and Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. *J Biol Chem*. 272(6), 3406-10. (1997).
89. Elstner E, Muller C, Koshizuka K, et al.: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. *Proc Natl Acad Sci U S A*. 95(15), 8806-11. (1998).
90. Murphy GJ and Holder JC: PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. *Trends Pharmacol Sci*. 21(12), 469-74. (2000).
91. Lazar MA: Becoming fat. *Genes Dev*. 16(1), 1-5. (2002).
92. Kersten S: Peroxisome proliferator activated receptors and obesity. *Eur J Pharmacol*. 440(2-3), 223-34. (2002).
93. Carey DG, Cowin GJ, Galloway GJ, et al.: Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. *Obes Res*. 10(10), 1008-15. (2002).
94. FDA: Withdrawal of Troglitazone and Cisapride. *JAMA*. 284(17), (2000).
95. EMEA, *Öffentlicher Mitteilungstext für GLUSTIN(Pioglitazon)*. 2004, [www.emea.eu.int/humandocs/PDFs/EPAR/Glustin/445300de1.pdf](http://www.emea.eu.int/humandocs/PDFs/EPAR/Glustin/445300de1.pdf).

96. Miyazaki Y, Mahankali A, Matsuda M, et al.: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. *Diabetes Care*. 24(4), 710-9. (2001).
97. Bogacka I, Xie H, Bray GA and Smith SR: The Effect of Pioglitazone on Peroxisome Proliferator-Activated Receptor- $\{\gamma\}$  Target Genes Related to Lipid Storage In Vivo. *Diabetes Care*. 27(7), 1660-1667. (2004).
98. Sander GE, West DW and Huggins CG: Inhibitors of the pulmonary angiotensin I-converting enzyme. *Biochim Biophys Acta*. 289(2), 392-400 (1972).
99. Cheung HS, Cushman DW, Sander GE, West DW and Huggins CG: Inhibition of homogeneous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of *Bothrops jararaca*. *Biochim Biophys Acta*. 293(2), 451-63 (1973).
100. Antonaccio MJ: Angiotensin converting enzyme (ACE) inhibitors. *Annu Rev Pharmacol Toxicol*. 2257-87 (1982).
101. Hochdruckliga D: Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. online, <http://www.paritaet.org/hochdruckliga/guidline.htm>, (2003).
102. Morice AH, Lowry R, Brown MJ and Higenbottam T: Angiotensin-converting enzyme and the cough reflex. *Lancet*. 2(8568), 1116-8 (1987).
103. Fletcher AE, Palmer AJ and Bulpitt CJ: Cough with angiotensin converting enzyme inhibitors: how much of a problem? *J Hypertens Suppl*. 12(2), S43-7 (1994).
104. Fox AJ, Lalloo UG, Belvisi MG, et al.: Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. *Nat Med*. 2(7), 814-7. (1996).
105. Trifilieff A, Da Silva A and Gies JP: Kinins and respiratory tract diseases. *Eur Respir J*. 6(4), 576-87 (1993).
106. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D and Menard J: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. *Circulation*. 92(4), 825-34. (1995).
107. Dudley DT, Panek RL, Major TC, et al.: Subclasses of angiotensin II binding sites and their functional significance. *Mol Pharmacol*. 38(3), 370-7 (1990).
108. Morck: Neue Arzneimittel 1995-2004. *Pharmazeutische Zeitung*, (1995-2004).
109. de Gasparo M, Catt KJ, Inagami T, Wright JW and Unger T: International union of pharmacology. XXIII. The angiotensin II receptors. *Pharmacol Rev*. 52(3), 415-72. (2000).
110. Kaschina E and Unger T: Angiotensin AT1/AT2 receptors: regulation, signalling and function. *Blood Press*. 12(2), 70-88 (2003).
111. Rockman HA, Koch WJ and Lefkowitz RJ: Seven-transmembrane-spanning receptors and heart function. *Nature*. 415(6868), 206-12. (2002).
112. Wruck CJ, Funke-Kaiser H, Pufe T, et al.: Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. *Arterioscler Thromb Vasc Biol*. 25(1), 57-64. Epub 2004 Nov 11. (2005).
113. Senbonmatsu T, Saito T, Landon EJ, et al.: A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. *Embo J*. 22(24), 6471-82. (2003).
114. Schiffrin EL and Touyz RM: Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. *J Am Coll Cardiol*. 42(5), 911-3 (2003).
115. Kirch W, Horn B and Schweizer J: Comparison of angiotensin II receptor antagonists. *Eur J Clin Invest*. 31(8), 698-706. (2001).

116. Verheijen I, Vanderheyden PM, De Backer JP and Vauquelin G: AT1 receptor antagonists. *Curr Med Chem Cardiovasc Hematol Agents*. 2(1), 69-77. (2004).
117. Israili ZH: Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. *J Hum Hypertens*. 14(Suppl 1), S73-86. (2000).
118. Chung O, Stoll M and Unger T: Physiologic and pharmacologic implications of AT1 versus AT2 receptors. *Blood Press Suppl*. 247-52 (1996).
119. Meffert S, Stoll M, Steckelings UM, Bottari SP and Unger T: The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. *Mol Cell Endocrinol*. 122(1), 59-67 (1996).
120. Lucius R, Gallinat S, Rosenstiel P, et al.: The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. *J Exp Med*. 188(4), 661-70 (1998).
121. Stoll M, Steckelings UM, Paul M, et al.: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. *J Clin Invest*. 95(2), 651-7 (1995).
122. Waeber B, Burnier M, Nussberger J and Brunner HR: Experience with angiotensin II antagonists in hypertensive patients. *Clin Exp Pharmacol Physiol Suppl*. 3S142-6 (1996).
123. Dendorfer A, Raasch W, Tempel K and Dominiak P: Interactions between the renin-angiotensin system (RAS) and the sympathetic system. *Basic Res Cardiol*. 93 Suppl 224-9 (1998).
124. Nap A, Balt JC, Pfaffendorf M and Van Zwieten PA: Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta. *J Hypertens*. 20(9), 1821-8 (2002).
125. Castellion AW and Fulton RW: Preclinical pharmacology of saralasin. *Kidney Int Suppl*, (9), S11-9 (1979).
126. Holck M, Bosse R, Fischli W, Gerold H and Escher E: An angiotensin II antagonist with strongly prolonged action. *Biochem Biophys Res Commun*. 160(3), 1350-6 (1989).
127. Pals DT, Masucci FD, Sipos F and Denning GS, Jr.: A specific competitive antagonist of the vascular action of angiotensin. II. *Circ Res*. 29(6), 664-72. (1971).
128. Kramer C, Sunkomat J, Witte J, et al.: Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. *Circ Res*. 90(7), 770-6 (2002).
129. Regitz-Zagrosek V and Unger Ts: Angiotensin-Rezeptorantagonisten(1. Auflage) Uni-Med Verlag, Science, Bremen-London-Boston, International Medical Publisher. 63-70 (2003).
130. Massiera F, Bloch-Faure M, Ceiler D, et al.: Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. *Faseb J*. 15(14), 2727-9. Epub 2001 Oct 15. (2001).
131. Lee MA, Bohm M, Paul M and Ganten D: Tissue renin-angiotensin systems. Their role in cardiovascular disease. *Circulation*. 87(5 Suppl), IV7-13 (1993).
132. Lewis EJ: The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. *Am J Hypertens*. 15(10 Pt 2), 123S-128S (2002).
133. Barnett AH, Bain SC, Bouter P, et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med*. 351(19), 1952-61. Epub 2004 Oct 31. (2004).



134. Devereux RB, Dahlof B, Kjeldsen SE, et al.: Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. *Ann Intern Med.* 139(3), 169-77 (2003).
135. Schernthaner G: [Progress in the prevention of type 2 diabetes]. *Wien Klin Wochenschr.* 115(21-22), 745-57 (2003).
136. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet.* 362(9386), 759-66 (2003).
137. Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet.* 363(9426), 2022-31. (2004).
138. Scheen AJ: Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. *Drugs.* 64(22), 2537-65. (2004).
139. Isami S, Kishikawa H, Araki E, et al.: Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway. *Diabetologia.* 39(4), 412-20 (1996).
140. Kishi K, Muromoto N, Nakaya Y, et al.: Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. *Diabetes.* 47(4), 550-8 (1998).
141. McCarty MF: ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes. *Med Hypotheses.* 60(6), 779-83 (2003).
142. Janke J, Engeli S, Gorzelniak K, Luft FC and Sharma AM: Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. *Diabetes.* 51(6), 1699-707. (2002).
143. Ichiki T, Labosky PA, Shiota C, et al.: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. *Nature.* 377(6551), 748-50. (1995).
144. Sambrook J, Fritsch EF and Maniatis Ts: Molecular Cloning: A Laboratory Manual.(1,2,3), New York, Spring Harbor Laboratory Press (1989).
145. Klebe RJ, Harriss JV, Sharp ZD and Douglas MG: A general method for polyethylene-glycol-induced genetic transformation of bacteria and yeast. *Gene.* 25(2-3), 333-41. (1983).
146. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 72:248-54. (1976).
147. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature.* 227(5259), 680-5. (1970).
148. Cherezov V, Fersi H and Caffrey M: Crystallization screens: compatibility with the lipidic cubic phase for in meso crystallization of membrane proteins. *Biophys J.* 81(1), 225-42. (2001).
149. Yu ZW, Buren J, Enerback S, et al.: Insulin can enhance GLUT4 gene expression in 3T3-F442A cells and this effect is mimicked by vanadate but counteracted by cAMP and high glucose--potential implications for insulin resistance. *Biochim Biophys Acta.* 1535(2), 174-85. (2001).
150. Guan HP, Ishizuka T, Chui PC, Lehrke M and Lazar MA: Corepressors selectively control the transcriptional activity of PPAR {gamma} in adipocytes. *Genes Dev.* 2828 (2005).
151. Mallow H, Trindl A and Loffler G: Production of angiotensin II receptors type one (AT1) and type two (AT2) during the differentiation of 3T3-L1 preadipocytes. *Horm Metab Res.* 32(11-12), 500-3. (2000).



152. Jones BH, Standridge MK and Moustaid N: Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. *Endocrinology*. 138(4), 1512-9. (1997).
153. Schling P and Schafer T: Human adipose tissue cells keep tight control on the angiotensin II levels in their vicinity. *J Biol Chem*. 277(50), 48066-75. Epub 2002 Aug 23. (2002).
154. Ailhaud G: Cross talk between adipocytes and their precursors: relationships with adipose tissue development and blood pressure. *Ann N Y Acad Sci*. 892:127-33. (1999).
155. Takahashi K, Bardhan S, Kambayashi Y, Shirai H and Inagami T: Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor, AT2. *Biochem Biophys Res Commun*. 198(1), 60-6. (1994).
156. Jung KM, Park KS, Oh JH, et al.: Activation of p38 mitogen-activated protein kinase and activator protein-1 during the promotion of neurite extension of PC-12 cells by 15-deoxy-delta12,14-prostaglandin J2. *Mol Pharmacol*. 63(3), 607-16. (2003).
157. Unger T: Pharmacology of AT1-receptor blockers. *Blood Press Suppl*, (3), 5-10. (2001).
158. Cesario RM, Klausning K, Razzaghi H, et al.: The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. *Mol Endocrinol*. 15(8), 1360-9. (2001).
159. Schulman IG, Shao G and Heyman RA: Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: intermolecular synergy requires only the PPARgamma hormone-dependent activation function. *Mol Cell Biol*. 18(6), 3483-94. (1998).
160. Jpenberg A, Tan NS, Gelman L, et al.: In vivo activation of PPAR target genes by RXR homodimers. *Embo J*. 23(10), 2083-91. Epub 2004 Apr 22. (2004).
161. Qi JS, Desai-Yajnik V, Greene ME, Raaka BM and Samuels HH: The ligand-binding domains of the thyroid hormone/retinoid receptor gene subfamily function in vivo to mediate heterodimerization, gene silencing, and transactivation. *Mol Cell Biol*. 15(3), 1817-25. (1995).
162. Leesnitzer LM, Parks DJ, Bledsoe RK, et al.: Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. *Biochemistry*. 41(21), 6640-50. (2002).
163. Yasar U, Forslund-Bergengren C, Tybring G, et al.: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. *Clin Pharmacol Ther*. 71(1), 89-98. (2002).
164. Stearns RA, Chakravarty PK, Chen R and Chiu SH: Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. *Drug Metab Dispos*. 23(2), 207-15. (1995).
165. Benson SC, Pershadsingh HA, Ho CI, et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. *Hypertension*. 43(5), 993-1002. Epub 2004 Mar 8. (2004).
166. Gil-Campos M, Canete RR and Gil A: Adiponectin, the missing link in insulin resistance and obesity. *Clin Nutr*. 23(5), 963-74. (2004).
167. Iwaki M, Matsuda M, Maeda N, et al.: Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. *Diabetes*. 52(7), 1655-63. (2003).
168. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L and Fogari R: Effects of telmisartan compared with eprosartan on blood pressure control, glucose

- metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. *Hypertens Res.* 27(7), 457-64. (2004).
169. Derosa G, Cicero AF, Bertone G, et al.: Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. *Clin Ther.* 26(8), 1228-36. (2004).
170. van Wijk JP, de Koning EJ, Martens EP and Rabelink TJ: Thiazolidinediones and blood lipids in type 2 diabetes. *Arterioscler Thromb Vasc Biol.* 23(10), 1744-9. Epub 2003 Aug 07. (2003).
171. Olansky L, Marchetti A and Lau H: Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. *Clin Ther.* 25(Suppl B), B64-80. (2003).
172. Khan MA, St Peter JV and Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. *Diabetes Care.* 25(4), 708-11. (2002).
173. Schoonjans K, Staels B and Auwerx J: The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. *Biochim Biophys Acta.* 1302(2), 93-109. (1996).
174. Auwerx J, Schoonjans K, Fruchart JC and Staels B: Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. *J Atheroscler Thromb.* 3(2), 81-9. (1996).
175. Schoonjans K, Watanabe M, Suzuki H, et al.: Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. *J Biol Chem.* 270(33), 19269-76. (1995).
176. Mukherjee R, Sun S, Santomena L, et al.: Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor alpha. *J Steroid Biochem Mol Biol.* 81(3), 217-25. (2002).
177. Elbrecht A, Chen Y, Adams A, et al.: L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. *J Biol Chem.* 274(12), 7913-22. (1999).
178. Berger J, Bailey P, Biswas C, et al.: Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. *Endocrinology.* 137(10), 4189-95. (1996).
179. Alarid ET, Bakopoulos N and Solodin N: Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. *Mol Endocrinol.* 13(9), 1522-34. (1999).
180. Zhu J, Gianni M, Kopf E, et al.: Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. *Proc Natl Acad Sci U S A.* 96(26), 14807-12. (1999).
181. Hauser S, Adelmant G, Sarraf P, et al.: Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. *J Biol Chem.* 275(24), 18527-33. (2000).
182. Syvala H, Vienonen A, Zhuang YH, et al.: Evidence for enhanced ubiquitin-mediated proteolysis of the chicken progesterone receptor by progesterone. *Life Sci.* 63(17), 1505-12. (1998).

183. Bellingham DL, Sar M and Cidlowski JA: Ligand-dependent down-regulation of stably transfected human glucocorticoid receptors is associated with the loss of functional glucocorticoid responsiveness. *Mol Endocrinol.* 6(12), 2090-102. (1992).
184. Takamura T, Nohara E, Nagai Y and Kobayashi K: Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPAR $\gamma$  mRNA expression in 3T3-L1 adipocytes. *Eur J Pharmacol.* 422(1-3), 23-9. (2001).
185. Rosenbaum SE and Greenberg AS: The short- and long-term effects of tumor necrosis factor- $\alpha$  and BRL 49653 on peroxisome proliferator-activated receptor (PPAR) $\gamma$ 2 gene expression and other adipocyte genes. *Mol Endocrinol.* 12(8), 1150-60. (1998).
186. Perrey S, Ishibashi S, Yahagi N, et al.: Thiazolidinedione- and tumor necrosis factor  $\alpha$ -induced downregulation of peroxisome proliferator-activated receptor  $\gamma$  mRNA in differentiated 3T3-L1 adipocytes. *Metabolism.* 50(1), 36-40. (2001).
187. Picard F, Gehin M, Annicotte J, et al.: SRC-1 and TIF2 control energy balance between white and brown adipose tissues. *Cell.* 111(7), 931-41 (2002).
188. Savkur RS and Burris TP: The coactivator LXXLL nuclear receptor recognition motif. *J Pept Res.* 63(3), 207-12. (2004).
189. Privalsky ML: The role of corepressors in transcriptional regulation by nuclear hormone receptors. *Annu Rev Physiol.* 66:315-60. (2004).
190. Cohen RN, Putney A, Wondisford FE and Hollenberg AN: The nuclear corepressors recognize distinct nuclear receptor complexes. *Mol Endocrinol.* 14(6), 900-14. (2000).
191. Hu X and Lazar MA: The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. *Nature.* 402(6757), 93-6. (1999).
192. Aranda A and Pascual A: Nuclear hormone receptors and gene expression. *Physiol Rev.* 81(3), 1269-304. (2001).
193. Xu HE, Stanley TB, Montana VG, et al.: Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR $\alpha$ . *Nature.* 415(6873), 813-7. (2002).
194. Hermanson O, Glass CK and Rosenfeld MG: Nuclear receptor coregulators: multiple modes of modification. *Trends Endocrinol Metab.* 13(2), 55-60. (2002).
195. Lemon B, Inouye C, King DS and Tjian R: Selectivity of chromatin-remodelling cofactors for ligand-activated transcription. *Nature.* 414(6866), 924-8. (2001).
196. Wallberg AE, Yamamura S, Malik S, Spiegelman BM and Roeder RG: Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1 $\alpha$ . *Mol Cell.* 12(5), 1137-49. (2003).
197. Voegel JJ, Heine MJ, Tini M, et al.: The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. *Embo J.* 17(2), 507-19 (1998).
198. Young PW, Buckle DR, Cantello BC, et al.: Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor  $\gamma$ . *J Pharmacol Exp Ther.* 284(2), 751-9. (1998).
199. Liu J, Knappenberger KS, Kack H, et al.: A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment. *Mol Endocrinol.* 17(3), 346-55. Epub 2002 Dec 05. (2003).
200. Miao B, Sun S, Santomenna LD, et al.: Ligand-induced coactivator recruitment to peroxisome proliferator-activated receptor  $\alpha$  characterized by fluorescence resonance energy transfer. *Methods Enzymol.* 357:180-8. (2002).

201. Zhou G, Cummings R, Li Y, et al.: Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. *Mol Endocrinol.* 12(10), 1594-604. (1998).
202. Kodera Y, Takeyama K, Murayama A, et al.: Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. *J Biol Chem.* 275(43), 33201-4. (2000).
203. Gerhold DL, Liu F, Jiang G, et al.: Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. *Endocrinology.* 143(6), 2106-18. (2002).
204. Katzenellenbogen JA, O'Malley BW and Katzenellenbogen BS: Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. *Mol Endocrinol.* 10(2), 119-31. (1996).
205. McKenna NJ and O'Malley BW: From ligand to response: generating diversity in nuclear receptor coregulator function. *J Steroid Biochem Mol Biol.* 74(5), 351-6. (2000).
206. Berger JP, Petro AE, Macnaul KL, et al.: Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. *Mol Endocrinol.* 17(4), 662-76. Epub 2003 Jan 16. (2003).
207. Juge-Aubry C, Pernin A, Favez T, et al.: DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5'-flanking region. *J Biol Chem.* 272(40), 25252-9. (1997).
208. Kishida K, Shimomura I, Nishizawa H, et al.: Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma. *J Biol Chem.* 276(51), 48572-9. Epub 2001 Oct 25. (2001).
209. Sato O, Kuriki C, Fukui Y and Motojima K: Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor alpha and gamma ligands. *J Biol Chem.* 277(18), 15703-11. Epub 2002 Feb 26. (2002).
210. Beale EG, Forest C and Hammer RE: Regulation of cytosolic phosphoenolpyruvate carboxykinase gene expression in adipocytes. *Biochimie.* 85(12), 1207-11. (2003).
211. Baumann CA, Chokshi N, Saltiel AR and Ribon V: Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene. *J Biol Chem.* 275(13), 9131-5. (2000).
212. Iida KT, Kawakami Y, Suzuki H, et al.: PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages. *FEBS Lett.* 520(1-3), 177-81. (2002).
213. Guan HP, Li Y, Jensen MV, et al.: A futile metabolic cycle activated in adipocytes by antidiabetic agents. *Nat Med.* 8(10), 1122-8 (2002).
214. El-Jack AK, Hamm JK, Pilch PF and Farmer SR: Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARgamma and C/EBPalpha. *J Biol Chem.* 274(12), 7946-51. (1999).
215. Hartman HB, Hu X, Tyler KX, Dalal CK and Lazar MA: Mechanisms regulating adipocyte expression of resistin. *J Biol Chem.* 277(22), 19754-61 (2002).
216. Suzuki R, Tobe K, Aoyama M, et al.: Expression of DGAT2 in white adipose tissue is regulated by central leptin action. *J Biol Chem.* 1818 (2004).

217. Floyd ZE and Stephens JM: STAT5A promotes adipogenesis in nonprecursor cells and associates with the glucocorticoid receptor during adipocyte differentiation. *Diabetes*. 52(2), 308-14. (2003).
218. Laudes M, Christodoulides C, Sewter C, et al.: Role of the POZ zinc finger transcription factor FBI-1 in human and murine adipogenesis. *J Biol Chem*. 279(12), 11711-8. Epub 2003 Dec 30. (2004).
219. Hasan RN, Phukan S and Harada S: Differential regulation of early growth response gene-1 expression by insulin and glucose in vascular endothelial cells. *Arterioscler Thromb Vasc Biol*. 23(6), 988-93. Epub 2003 Apr 10. (2003).
220. Harja E, Bucciarelli LG, Lu Y, et al.: Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. *Circ Res*. 94(3), 333-9. Epub 2003 Dec 11. (2004).
221. Watson RT, Kanzaki M and Pessin JE: Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes. *Endocr Rev*. 25(2), 177-204. (2004).
222. Nugent C, Prins JB, Whitehead JP, et al.: Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. *Mol Endocrinol*. 15(10), 1729-38. (2001).
223. Wu Z, Xie Y, Morrison RF, Bucher NL and Farmer SR: PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. *J Clin Invest*. 101(1), 22-32. (1998).
224. Armoni M, Kritiz N, Harel C, et al.: Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. *J Biol Chem*. 278(33), 30614-23. Epub 2003 May 29. (2003).
225. Olefsky JM: Mechanisms of decreased insulin responsiveness of large adipocytes. *Endocrinology*. 100(4), 1169-77. (1977).
226. Nolte RT, Wisely GB, Westin S, et al.: Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. *Nature*. 395(6698), 137-43. (1998).
227. Oberfield JL, Collins JL, Holmes CP, et al.: A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. *Proc Natl Acad Sci U S A*. 96(11), 6102-6. (1999).
228. Ostberg T, Svensson S, Selen G, et al.: A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. *J Biol Chem*. 1515 (2004).
229. Unger T: Blood pressure lowering and renin-angiotensin system blockade. *J Hypertens*. 21(Suppl 6), S3-7. (2003).
230. Engeli S, Schling P, Gorzelniak K, et al.: The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? *Int J Biochem Cell Biol*. 35(6), 807-25. (2003).
231. Schling P: Expression of angiotensin II receptors type 1 and type 2 in human preadipose cells during differentiation. *Horm Metab Res*. 34(11-12), 709-15. (2002).
232. Saint-Marc P, Kozak LP, Ailhaud G, Darimont C and Negrel R: Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. *Endocrinology*. 142(1), 487-92. (2001).

233. Massiera F, Saint-Marc P, Seydoux J, et al.: Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern? *J Lipid Res.* 44(2), 271-9. Epub 2002 Nov 04. (2003).
234. Wu Y, Chin WW, Wang Y and Burriss TP: Ligand and coactivator identity determines the requirement of the charge clamp for coactivation of the peroxisome proliferator-activated receptor gamma. *J Biol Chem.* 278(10), 8637-44. Epub 2002 Dec 26. (2003).
235. Floyd ZE and Stephens JM: Control of peroxisome proliferator-activated receptor gamma2 stability and activity by SUMOylation. *Obes Res.* 12(6), 921-8 (2004).
236. Camp HS, Whitton AL and Tafuri SR: PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes. *FEBS Lett.* 447(2-3), 186-90. (1999).
237. Ebdrup S, Pettersson I, Rasmussen HB, et al.: Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. *J Med Chem.* 46(8), 1306-17. (2003).
238. Jaradat MS, Wongsud B, Phornchirasilp S, et al.: Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. *Biochem Pharmacol.* 62(12), 1587-95. (2001).
239. Robertson JF: Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. *Cancer Treat Rev.* 30(8), 695-706. (2004).
240. Ring A and Dowsett M: Mechanisms of tamoxifen resistance. *Endocr Relat Cancer.* 11(4), 643-58. (2004).
241. Shiau AK, Barstad D, Loria PM, et al.: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell.* 95(7), 927-37. (1998).
242. Shang Y and Brown M: Molecular determinants for the tissue specificity of SERMs. *Science.* 295(5564), 2465-8. (2002).
243. Schacke H, Schottelius A, Docke WD, et al.: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. *Proc Natl Acad Sci U S A.* 101(1), 227-32. Epub 2003 Dec 23. (2004).
244. Fujimoto M, Masuzaki H, Tanaka T, et al.: An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. *FEBS Lett.* 576(3), 492-7. (2004).
245. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK and Krekler M: Selective angiotensin II receptor antagonist reduces insulin resistance in obese Zucker rats. *Hypertension.* 38(4), 884-90. (2001).
246. Qi N, Pravenec M, Ho CI, et al. *Telmisartan is a Dual ARB and PPAR gamma Activator That Limits Weight Gain, Body Fat Accumulation, and Adipocyte Size in Rats Fed High Fat, High Carbohydrate Diets.* in *Council for High Blood Pressure Research.* 2004. Chicago.
247. Yamauchi T, Kamon J, Waki H, et al.: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. *J Biol Chem.* 276(44), 41245-54. Epub 2001 Aug 31. (2001).
248. Anderson DC, Jr.: Pharmacologic prevention or delay of type 2 diabetes mellitus. *Ann Pharmacother.* 39(1), 102-9. Epub 2004 Nov 23. (2005).

249. Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. *Diabetes*. 51(9), 2796-803. (2002).
250. Durbin RJ: Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. *Diabetes Obes Metab*. 6(4), 280-5. (2004).
251. Stangier J, Su CA and Roth W: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. *J Int Med Res*. 28(4), 149-67. (2000).
252. Doggrell SA: Telmisartan - killing two birds with one stone. *Expert Opin Pharmacother*. 5(11), 2397-400. (2004).
253. Zimmermann M and Unger T: Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme. *Expert Opin Pharmacother*. 5(5), 1201-8. (2004).
254. Pershadsingh HA and Kurtz TW: Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. *Diabetes Care*. 27(4), 1015. (2004).
255. Honjo S, Nichi Y, Wada Y, Hamamoto Y and Koshiyama H: Possible beneficial effect of telmisartan on glycemetic control in diabetic subjects. *Diabetes Care*. 28(2), 498. (2005).